Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLALOC-2: DRV/c + 3TC vs DRV/c + TAF/FTC in Virologically Suppressed HIV-1 Patients
NCT07678268Phase 4Recruiting
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
A Phase 4 trial of darunavir, cobicistat, lamivudine, tenofovir alafenamide, emtricitabine in human immunodeficiency virus infection (HIV), sponsored by Instituto Mexicano del Seguro Social. Started Jul 2025; status: recruiting.
02
Drugs
darunavircobicistatlamivudinetenofovir alafenamideemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07678268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678268.